AR128785A1 - COMPOSICIONES LIOFILIZADAS QUE COMPRENDEN PARTICULAS DE VIRUS ADENOASOCIADO RECOMBINANTE (rAAV) - Google Patents
COMPOSICIONES LIOFILIZADAS QUE COMPRENDEN PARTICULAS DE VIRUS ADENOASOCIADO RECOMBINANTE (rAAV)Info
- Publication number
- AR128785A1 AR128785A1 ARP230100629A ARP230100629A AR128785A1 AR 128785 A1 AR128785 A1 AR 128785A1 AR P230100629 A ARP230100629 A AR P230100629A AR P230100629 A ARP230100629 A AR P230100629A AR 128785 A1 AR128785 A1 AR 128785A1
- Authority
- AR
- Argentina
- Prior art keywords
- raav
- particles
- concentration
- associated virus
- recombinant adeno
- Prior art date
Links
- 241000702421 Dependoparvovirus Species 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000004067 bulking agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263319657P | 2022-03-14 | 2022-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128785A1 true AR128785A1 (es) | 2024-06-12 |
Family
ID=85979703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100629A AR128785A1 (es) | 2022-03-14 | 2023-03-14 | COMPOSICIONES LIOFILIZADAS QUE COMPRENDEN PARTICULAS DE VIRUS ADENOASOCIADO RECOMBINANTE (rAAV) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230293724A1 (https=) |
| EP (1) | EP4493162A1 (https=) |
| JP (1) | JP2025509566A (https=) |
| KR (1) | KR20250002229A (https=) |
| CN (1) | CN119072302A (https=) |
| AR (1) | AR128785A1 (https=) |
| AU (1) | AU2023233503A1 (https=) |
| CA (1) | CA3245651A1 (https=) |
| IL (1) | IL315322A (https=) |
| TW (1) | TW202406560A (https=) |
| WO (1) | WO2023177626A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025076729A1 (zh) * | 2023-10-11 | 2025-04-17 | 朗信启昇(苏州)生物制药有限公司 | 包含aav的药物组合物及其制备方法 |
| WO2025114524A1 (en) * | 2023-11-30 | 2025-06-05 | Uniqure Biopharma B.V. | Formulations for viral drug products |
| WO2025185606A1 (en) * | 2024-03-04 | 2025-09-12 | Nanjing Legend Biotech Co., Ltd. | Composition for cryoprotection of viral vector or vlp |
| WO2025188316A1 (en) * | 2024-03-08 | 2025-09-12 | Jaguar Gene Therapy, Llc | Aav pharmaceutical formulations and methods thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021009370A2 (pt) * | 2018-11-14 | 2021-08-17 | Regenxbio Inc. | método de tratamento da doença de batten cln2, composição farmacêutica e kit |
| SG11202107645RA (en) * | 2019-01-18 | 2021-08-30 | Voyager Therapeutics Inc | Methods and systems for producing aav particles |
| TW202332458A (zh) * | 2019-04-19 | 2023-08-16 | 美商銳進科斯生物股份有限公司 | 腺相關病毒載體調配物及方法 |
| WO2021071835A1 (en) * | 2019-10-07 | 2021-04-15 | Regenxbio Inc. | Adeno-associated virus vector pharmaceutical composition and methods |
| TW202144575A (zh) * | 2020-04-03 | 2021-12-01 | 美商拜奧馬林製藥公司 | 使用ａａｖ及治療調配物之苯酮尿症治療 |
-
2023
- 2023-03-13 WO PCT/US2023/015112 patent/WO2023177626A1/en not_active Ceased
- 2023-03-13 CA CA3245651A patent/CA3245651A1/en active Pending
- 2023-03-13 EP EP23716010.6A patent/EP4493162A1/en active Pending
- 2023-03-13 KR KR1020247034157A patent/KR20250002229A/ko active Pending
- 2023-03-13 US US18/120,762 patent/US20230293724A1/en active Pending
- 2023-03-13 IL IL315322A patent/IL315322A/en unknown
- 2023-03-13 TW TW112109096A patent/TW202406560A/zh unknown
- 2023-03-13 AU AU2023233503A patent/AU2023233503A1/en active Pending
- 2023-03-13 CN CN202380035210.1A patent/CN119072302A/zh active Pending
- 2023-03-13 JP JP2024554782A patent/JP2025509566A/ja active Pending
- 2023-03-14 AR ARP230100629A patent/AR128785A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230293724A1 (en) | 2023-09-21 |
| TW202406560A (zh) | 2024-02-16 |
| JP2025509566A (ja) | 2025-04-11 |
| EP4493162A1 (en) | 2025-01-22 |
| AU2023233503A1 (en) | 2024-09-19 |
| KR20250002229A (ko) | 2025-01-07 |
| CA3245651A1 (en) | 2023-09-21 |
| WO2023177626A1 (en) | 2023-09-21 |
| IL315322A (en) | 2024-10-01 |
| CN119072302A (zh) | 2024-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR128785A1 (es) | COMPOSICIONES LIOFILIZADAS QUE COMPRENDEN PARTICULAS DE VIRUS ADENOASOCIADO RECOMBINANTE (rAAV) | |
| Fourrier | Severe sepsis, coagulation, and fibrinolysis: dead end or one way? | |
| JP6173547B2 (ja) | ボツリヌム毒素の凍結乾燥製剤 | |
| ATE539744T1 (de) | Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem | |
| UY25055A1 (es) | Formulaciones farmacéuticas que contienen voriconazol | |
| AR012540A1 (es) | COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN | |
| CO5700796A2 (es) | Composiciones que contienen piperacilina y tazobactam utiles para inyecciones | |
| EA200500406A1 (ru) | Активный ингибитор серинпротеазы hcv | |
| FI964285A0 (fi) | Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet | |
| JP2007262090A (ja) | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 | |
| KR950703987A (ko) | G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf) | |
| CR20210318A (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| ES2063365T3 (es) | Composiciones anticoagulantes basadas en el factor xa. | |
| BR0012919A (pt) | Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv | |
| JP2021509809A (ja) | コロナウイルス感染症の治療または予防に使用するためのプロテアーゼ活性を有するペプチド | |
| DE602004015725D1 (de) | Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors | |
| ES2224917T1 (es) | Composiciones farmaceuticas de agente fibrinolitico. | |
| HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
| AR034226A2 (es) | Procedimiento perfeccionado para estabilizar proteinas. | |
| KR20020060080A (ko) | 혈액 응고 제ⅶ 인자를 활성화시키는 프로테아제 또는이의 프로효소의 안정화 액제 | |
| US20160129115A1 (en) | Formulations of liquid stable antithrombin | |
| AR126417A1 (es) | Composición farmacéutica de virus no encapsulado | |
| BR112023019201A2 (pt) | Composição farmacêutica aquosa ou composição farmacêutica liofilizada | |
| EP3636275A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEOVASCULAR DISEASES WITH TYPE I COLLAGEN AND FACTOR PEPTIDE FROM PIGMENT EPITHELA AS ACTIVE INGREDIENTS | |
| CN105777858B (zh) | 多种抗体的复合稳定剂及其使用方法 |